Synageva BioPharma Corp

Synageva BioPharma — Trimeris — Merger or Acquisition (September 2011)

32 slides from Synageva BioPharma's merger presentation, Sep 7, 2011

  1. Slide 1: Company Presentation September 2011

    © Copyright 2011 Synageva BioPharma™ Company Presentation September 2011

  2. Slide 2: Forward-Looking Statements

    2 © Copyright 2011 Synageva BioPharma™ Forward-Looking Statements These materials and oral statements made from time to time by Synageva representatives in respect of the same subject matter may contain “forward-looking statements.” These statements can be identified by introductory words such as “e

  3. Slide 3: Vehicle Focus Count-Down: Synageva Strategy & Direction

    3 © Copyright 2011 Synageva BioPharma™ Vehicle Focus Count-Down Synageva Strategy & Direction

  4. Slide 4: Synageva Transaction

    4 © Copyright 2011 Synageva BioPharma™ Synageva Transaction Deal Synageva and Trimeris merge in all-stock transaction 3:1 exchange ratio Transaction has been unanimously approved by both boards Rationale Provides Synageva financial resources to aggressively pursue corporate strategy Gives Synageva a

  5. Slide 5: Synageva Investment Highlights

    Synageva Investment Highlights 5 © Copyright 2011 Synageva BioPharma™ Rare Disease Experience Unmet Medical Need ERT for LSD – Model is Predictive Patient Dosing Commenced Pull-through Expertise Robust, Efficient and Scalable Team Rare Disease Lead Product Status Commercial Manufacturing

  6. Slide 6: Proven Management Team

    6 © Copyright 2011 Synageva BioPharma™ Sanj K. Patel Carsten Boess Mark Goldberg Eric Grinstead Anthony Quinn Tara O’Meara Joe DeCourcey Proven Management Team Chief Executive Officer Product Development Chief Financial Officer Commercial Operations Chief Medical Officer Clinical Operations Manufact

  7. Slide 7: Synageva Pipeline

    7 © Copyright 2011 Synageva BioPharma™ Program Therapeutic Disease Development Status Regulatory Opportunity Synageva Pipeline SBC-102 (rhLAL) SBC-103 (rhNAGLU) SBC-104 SBC-105 SBC-106 Recombinant Lysosomal Acid Lipase Recombinant -N-acetyl- glucosaminidase Extra Cellular Protein Enzyme Replacement

  8. Slide 8: Lead Program ERT for Lysosomal Acid Lipase Deficiency (beselipase alfa)

    Lead Program 8 © Copyright 2011 Synageva BioPharma™ ERT for Lysosomal Acid Lipase Deficiency (beselipase alfa)* *Name under review by INN

  9. Slide 9: LAL Deficiency Disease Mechanism

    © Copyright 2011 Synageva BioPharma™ 9 LDL LDL receptors coated vesicle Cholesterol esters & TG FFA Free Cholesterol Free cholesterol and fatty acids are key regulators of lipid synthesis lysosome ENDOCYTOSIS Liver lipid content in model of LAL Deficiency Cholesteryl Ester Triglyceride LAL Deficient

  10. Slide 10: SBC-102 Late Onset LAL Deficiency (CESD)

    10 © Copyright 2011 Synageva BioPharma™ SBC-102 Late Onset LAL Deficiency (CESD) Shortened lifespan and morbidity Prominent hepatic manifestations – Fatty liver – Elevated transaminases – Fibrosis – Liver failure Other manifestations: splenomegaly, type II hyperlipidemia Rare disease in a common phe

  11. Slide 11: SBC-102 Early Onset LAL Deficiency (Wolman)

    © Copyright 2011 Synageva BioPharma™ 11 SBC-102 Early Onset LAL Deficiency (Wolman) Prominent hepatic and GI manifestations – Hepatomegaly and liver failure – Splenomegaly – Persistent vomiting – Abdominal distension – Profound growth failure Adrenal calcification Rapidly progressive and fatal 4.4 6

  12. Slide 12: SBC-102 Targeting and Activity

    12 © Copyright 2011 Synageva BioPharma™ 0 0.16 0.5 1.6 5 SBC-102 T argeting and Activity Terminal mannose/GlcNac and mannose-6-phosphate (M6P) for targeted delivery Uptake into key cells, including macrophages Lysosomal localization demonstrated Corrects enzyme deficiency Lysotracker red Overlap ima

  13. Slide 13: SBC-102 Corrects Key Disease Related Abnormalities

    13 Untreated © Copyright 2011 Synageva BioPharma™ SBC-102 Corrects Key Disease Related Abnormalities Normal 4 weeks 8 weeks Normalizes liver LAL Deficient

  14. Slide 14: SBC-102 Rapid Correction of Growth Failure in LAL Model

    14 © Copyright 2011 Synageva BioPharma™ SBC-102 Rapid Correction of Growth Failure in LAL Model Normal LAL Deficient SBC-102 Treated, qw

  15. Slide 15: SBC-102 Efficacy With Every Other Week Dosing

    © Copyright 2011 Synageva BioPharma™ 15 SBC-102 Efficacy With Every Other Week Dosing Liver Spleen Marked Reduction In Liver Cholesteryl Ester Content Across A Broad Range Of Doses LAL Deficient Normal

  16. Slide 16: SBC-102 ERT Models Predict Efficacy and Dose

    Frequency mg/kg 16 © Copyright 2011 Synageva BioPharma™ Therapy Pre-Clinical Effective Dose Approved Dose Disease Model Key Results SBC-102 ERT Models Predict Efficacy and Dose Aldurazyme 0.5-2mg/kg once weekly (canine) QW 0.58 Lysosomal targeting & substrate reduction Fabrazyme 0.3-3mg/kg twice mon

  17. Slide 17: SBC-102 Clinical Development Timeline

    Conventional Development Programs 17 © Copyright 2011 Synageva BioPharma™ SBC-102 Clinical Development COMMERCIALIZATION Proof of concept established in disease model Small patient numbers accelerate development timelines (~5 years vs 5-10 years for common diseases) Patient dosing initiated within 3

  18. Slide 18: SBC-102 Clinical Development Late Onset (CESD)

    18 Phase I/II Open-Label Randomized, Double-Blind, Placebo-controlled Trial © Copyright 2011 Synageva BioPharma™ SBC-102 Clinical Development Late Onset (CESD) Adult patients with liver dysfunction due to LAL Deficiency Open label dose escalation 4 week dosing 3 dose levels Multicenter N = 9 Patient

  19. Slide 19: SBC-102 Clinical Development Early Onset (Wolman)

    19 Phase I/II Open-Label Open-Label Long-term Extension © Copyright 2011 Synageva BioPharma™ SBC-102 Clinical Development Early Onset (Wolman) Growth failure in children due to LAL Deficiency Open label dose escalation 4 month dosing Multicenter N= 8 Active Phase I/II Open-Label Secondary endpoints:

  20. Slide 20: SBC-102 Clinical and Regulatory Milestones

    20 © Copyright 2011 Synageva BioPharma™ SBC-102 Clinical and Regulatory Milestones IND filed on schedule and cleared within 30 days EU CTAs filed 3 months ahead of schedule US & EU orphan drug designations granted 2010 Fast Track designation granted by the FDA Clinical production for studies on sche

  21. Slide 21: SBC-102 Compassionate Use: Patient Data

    © Copyright 2011 Synageva BioPharma™ 21 SBC-102 Compassionate Use: Patient Data An infant with LAL Deficiency has received treatment with SBC-102 on a compassionate use basis – Presented with anemia, increasingly abnormal liver function tests, and growth failure prior to treatment – Child has receiv

  22. Slide 22: ERT for MPS IIIB / Sanfilippo B SBC-103 (rhNAGLU)

    22 © Copyright 2011 Synageva BioPharma™ ERT for MPS IIIB / Sanfilippo B SBC-103 (rhNAGLU)

  23. Slide 23: SBC-103 MPS IIIB / Sanfilippo B

    © Copyright 2011 Synageva BioPharma™ 23 SBC-103 MPS IIIB / Sanfilippo B Heparan sulfate accumulation in CNS, liver, spleen, skin and joints May affect as many as 8 lives per million Progressive mental impairment with sleep disturbances and behavioral manifestations – Severe phenotype - wheelchair de

  24. Slide 24: SBC-103 NAGLU Production for ERT

    24 © Copyright 2011 Synageva BioPharma™ SBC-103 NAGLU Production for ERT Historical attempts to produce NAGLU ERT for MPS IIIB have failed due to lack of cell uptake Yogalingham G et al, 2000 NAG (nmol/h per mg) Normal fibroblasts 25.12 ± 2.23 MPS-IIIB fibroblasts 0.101 ± 0.025 MPS-IIIB fibroblasts

  25. Slide 25: Synageva Expression Platform

    25 © Copyright 2011 Synageva BioPharma™ Synageva Expression Platform Proprietary Vector System Human Biopharmaceutical Expression in Egg White FDA-accepted Aseptic Protein Harvest GMP compliant facilities Automated commercial scale infrastructure Finished Product Consistent and Reliable Scale-up Pur

  26. Slide 26: SBC-102 Commercial: Ultra-Orphan Opportunity

    Drug Indication Estimated Prevalence 26 © Copyright 2011 Synageva BioPharma™ SBC-102 Commercial: Ultra-Orphan Opportunity SBC-102 Cerezyme Fabrazyme Myozyme Soliris SBC-103 LAL Deficiency Type I Gaucher Disease Fabry Disease Pompe Disease PNH MPS IIIB/ Sanfilippo B 1 in 59,000 to 86,000 1 in 40,000

  27. Slide 27: SBC-102 Commercial: Finding Patients

    © Copyright 2011 Synageva BioPharma™ 27 Right Right Right Test SBC-102 Commercial: Finding Patients Practice Patient ~17,000 homozygotes with LAL mutation Enzyme DNA Estimated distribution for US, EU and BR Estimated distribution for US, EU and BR Simple blood test Enzyme Assay DNA Sequencing Lab Pr

  28. Slide 28: SBC-102 Commercial: Rare & Devastating Disease in a Common Phenotype

    28 © Copyright 2011 Synageva BioPharma™ SBC-102 Commercial: Rare & Devastating Disease in a Common Phenotype 30-60M Americans have NAFLD 6-10M Americans have NASH 6K Americans are predicted to have CESD http://www.digestive.niddk.nih.gov/ddiseases/pubs/NASH/ Muntoni, et al; “Prevalence of Cholestery

  29. Slide 29: Synageva Value Drivers in Two Distinct Stages

    Investing in the future Valued as a clinical stage biotech First-ever ERT for LAL in humans Proof of Concept Established Human Data on SBC-102 Pipeline products entering clinic Filing and Approval for SBC-102 Commercial-stage biotech company Potential Five product introductions expected Valued on re

  30. Slide 30: Summary

    30 © Copyright 2011 Synageva BioPharma™ Summary Trimeris cash ending Q2 2011 was approx $52 million Synageva cash ending Q2 2011 was approx $18 million May 25th, 2011 Trimeris signed new agreement with Roche: Trimeris received $4.9 million upfront fee Trimeris to receive a 16% royalty on global sale

  31. Slide 31: Synageva Pipeline of Opportunity

    Program Therapeutic Disease Development Status Regulatory Opportunity 31 © Copyright 2011 Synageva BioPharma™ Synageva Pipeline of Opportunity SBC-102 (rhLAL) SBC-103 (rhNAGLU) SBC-104 SBC-105 SBC-106 Recombinant Lysosomal Acid Lipase Recombinant -N-accetyl- glucosaminidase Extra Cellular Protein En

  32. Slide 32: About Synageva BioPharma Corp.

    © Copyright 2011 Synageva BioPharma™ About Synageva BioPharma Corp. Synageva is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. SBC-102 has been gr

Trimeris — Merger or Acquisition (September 2011) on 6ix